Intervacc
Swedish animal-health biotechnology group developing veterinary vaccines using recombinant fusion proteins. The organisation combines in-house research and development, an ISO-accredited diagnostic laboratory, a regional commercial sales subsidiary and collaborations with academic and contract-research partners. Core activities include recombinant antigen discovery and design, preclinical and clinical evaluation in target species, regulatory submissions for veterinary biologics, and commercialisation in European and select international markets.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Equine vaccine against strangles (recombinant fusion protein vaccine)
A recombinant fusion-protein vaccine candidate developed to protect horses against strangles caused by Streptococcus equi; progressed through clinical development and subject to regulatory submissions for duration-of-immunity claims.
Porcine vaccine candidate against Streptococcus suis (recombinant fusion protein vaccine)
Vaccine in development to protect piglets against Streptococcus suis, based on fused recombinant antigens; evaluated in proof-of-concept and challenge studies including maternal vaccination strategies.
Bovine mastitis vaccine candidate (recombinant fusion protein approach)
Vaccine candidate targeting Staphylococcus aureus mastitis in dairy cattle using fused recombinant antigens to elicit protective immunity.
INV274
INV412 is a vaccine candidate project against infections caused by Staphylococcus aureus, aiming to prevent bovine mastitis using recombinant proteins.
INV412
INV412 is a vaccine candidate project against infections caused by Staphylococcus aureus, aiming to prevent bovine mastitis using recombinant proteins.
Strangvac
A modern, efficient and safe vaccine against strangles in horses, developed using recombinant fusion proteins.
Equine vaccine against strangles (recombinant fusion protein vaccine)
A recombinant fusion-protein vaccine candidate developed to protect horses against strangles caused by Streptococcus equi; progressed through clinical development and subject to regulatory submissions for duration-of-immunity claims.
Porcine vaccine candidate against Streptococcus suis (recombinant fusion protein vaccine)
Vaccine in development to protect piglets against Streptococcus suis, based on fused recombinant antigens; evaluated in proof-of-concept and challenge studies including maternal vaccination strategies.
Bovine mastitis vaccine candidate (recombinant fusion protein approach)
Vaccine candidate targeting Staphylococcus aureus mastitis in dairy cattle using fused recombinant antigens to elicit protective immunity.
INV274
INV412 is a vaccine candidate project against infections caused by Staphylococcus aureus, aiming to prevent bovine mastitis using recombinant proteins.
INV412
INV412 is a vaccine candidate project against infections caused by Staphylococcus aureus, aiming to prevent bovine mastitis using recombinant proteins.
Strangvac
A modern, efficient and safe vaccine against strangles in horses, developed using recombinant fusion proteins.
Services
ISO/IEC 17025-accredited on-site laboratory testing including bacteriology, mycology and antimicrobial susceptibility testing using microdilution methods.
ISO/IEC 17025-accredited on-site laboratory testing including bacteriology, mycology and antimicrobial susceptibility testing using microdilution methods.
Expertise Areas
- Veterinary vaccine development
- Recombinant antigen discovery and design
- Preclinical animal challenge models
- Clinical trial management in veterinary species
Key Technologies
- Recombinant fusion protein vaccines
- Bioinformatic antigen identification
- Animal challenge models
- Serology and correlates-of-protection analysis
News & Updates
AGM adopted financial statements, authorised share issuance up to 10%, and approved a long-term incentive programme; board re-elections and appointment of new chair were resolved.
Half-year financial and operational results published, with CEO comments on clinical data, market adoption and international expansion plans.
Regulatory variation submitted to extend stated duration of immunity for the equine strangles vaccine to 12 months, based on identified correlate of protection data.
Initial shipment of vaccine doses authorised for import into New Zealand under a Special Circumstances Permit; formal registration planned for future market entry.
Evaluation showed US strains comparable to those used in European studies, supporting progression of an approximately 600-horse safety study in the United States.
Piglets from vaccinated sows showed significantly fewer clinical signs after experimental Streptococcus suis challenge, supporting further development of a porcine vaccine candidate.
AGM adopted financial statements, authorised share issuance up to 10%, and approved a long-term incentive programme; board re-elections and appointment of new chair were resolved.
Half-year financial and operational results published, with CEO comments on clinical data, market adoption and international expansion plans.
Regulatory variation submitted to extend stated duration of immunity for the equine strangles vaccine to 12 months, based on identified correlate of protection data.
Initial shipment of vaccine doses authorised for import into New Zealand under a Special Circumstances Permit; formal registration planned for future market entry.
Evaluation showed US strains comparable to those used in European studies, supporting progression of an approximately 600-horse safety study in the United States.
Piglets from vaccinated sows showed significantly fewer clinical signs after experimental Streptococcus suis challenge, supporting further development of a porcine vaccine candidate.